Polycystic ovary syndrome in adolescents
- Obstetrics & Gynecology International Journal
Edgar Allan Villagomez mendoza,1 Manuel Martinez Meraz2
Objective: To propose to the clinical evidence available in the literature based on the criteria, recommendations and implications in addressing adolescent patients which condition decisions that impact treatment and follow-up to adulthood.
Method: Search was conducted in PubMed, Uptodate, Medical Subjetc Headings of articles published in English with the following keywords (Mesh): Polycystic ovary syndrome in adolescents, metabolic syndrome, hyperandrogenism in adolescent disorders menstrual pattern in adolescents. Inclusion criteria: systematic review and meta-analysis.
Results: 24 articles were selected, among them 10 are review articles, 11 original studies, 2 meta-analyzes and one consensus. Diagnostic criteria overlap with the physiological changes including clinical manifestations of hyperandrogenism and disorders in menstrual pattern in which mention should be made to diagnose polycystic ovary syndrome in this population, considering that the phenotype change through the reproductive life and teens have a heterogeneous ovarian morphology was proposed that the diagnosis was later confirmed the 18 years the first-line treatment includes oral contraceptives, change in lifestyle, use of insulin sensitizers to improve cardiovascular risk and alterations associated metabolic,
Conclusion: Polycystic ovary syndrome in adolescents is a challenging diagnosis for the clinician, and there has been a consensus that persistent unexplained hyperandrogenic anovulation using age appropriate and stage are criteria appropriate diagnostic ovary syndrome standards polycystic adolescents, be warned by consensus not to label hyperandrogenic adolescents as polycystic ovary syndrome if the menstrual abnormality has not persisted for 2 years or more before that time, it is recommended to consider patients as at risk of syndrome polycystic ovary, early diagnosis and early treatment radically change the prevalence of comorbiditiesit should promote a holistic approach to maximize the future health of our patients.
Polycystic ovary syndrome, Polycystic ovary syndrome in adolescents, Hyperandrogenism in adolescents, Menstrual disorders in adolescent pattern, Contraception, Metabolic syndrome, Follicle stimulating hormone, Luteinizing hormone, Dehydroepiandrosterone, Insulin-like growth factor 1, Gamma-aminobutyric acid, LH receptor choriogonadotropin, Nerve fibers, Central obesity, Abnormal for gynecological age